Primarycompositeoutcome:All-causemortality, MI,stroke: 13.1% vs. 16.3%,p = 0.4330-day: CVA: 2.8% vs. 3.0%,p = 0.94,permanentpacemaker implantation: 34.1% vs. 1.6%,p < 0.0011-year:Moderate to severe aorticregurgitation:15.7% vs. 0.9%,p < 0.001
Trial design:All-comers with severe degenerative aortic stenosis (median STS PROM 3%) were randomized in a 1:1 fashion to either TAVR or SAVR. They were followed for 1 year.
ThyregodH, et al. J AmCollCardiol2015;Mar 15:[Epub]
TAVR(n = 145)
Amongpatients with severe degenerative aortic stenosis with mostly low STS PROM scores, TAVR withCoreValveself-expanding prosthesishas similar1-year clinical outcomes asSAVRTAVRpatients had more aortic regurgitation, less symptomaticbenefit, anda higher need for a permanentpacemaker
(p = 0.43)